Jonathan Cebon

List of Publications by Year
in descending order

158 papers	17,738 citations	30047 54 h-index	14197 128 g-index
162 all docs	162 docs citations	162 times ranked	25380 citing authors

#	Article	IF	Citations
1	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 2022, 162, 22-33.	1.3	28
2	Migratory cues controlling Bâ€lymphocyte trafficking in human lymph nodes. Immunology and Cell Biology, 2021, 99, 49-64.	1.0	15
3	Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. OncoImmunology, 2021, 10, 1908771.	2.1	21
4	Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses. Cancers, 2021, 13, 1805.	1.7	2
5	Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. Cancer Cell, 2021, 39, 592-593.	7.7	41
6	A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discovery, 2021, 7, 122.	2.0	23
7	PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. Frontiers in Immunology, 2021, 12, 672521.	2.2	13
8	Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nature Immunology, 2021, 22, 851-864.	7.0	97
9	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. Clinical Cancer Research, 2021, 27, 5280-5288.	3.2	21
10	Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. , 2021, 9, e003156.		6
11	A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response. Journal of Investigative Dermatology, 2020, 140, 869-877.e16.	0.3	15
12	Butyrophilin 2A1 is essential for phosphoantigen reactivity by Î³Î´ T cells. Science, 2020, 367, .	6.0	275
13	Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers. JAMA Oncology, 2020, 6, 1405.	3.4	157
14	Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma. Cancer Immunology Research, 2020, 8, 1322-1334.	1.6	45
15	Sex differences in oncogenic mutational processes. Nature Communications, 2020, 11, 4330.	5.8	60
16	Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. BMC Nephrology, 2020, 21, 391.	0.8	20
17	BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. Cell Death Discovery, 2020, 6, 114.	2.0	13
18	Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. Clinical Cancer Research, 2020, 26, 4454-4459.	3.2	110

#	Article	IF	Citations
19	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
20	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clinical Cancer Research, 2020, 26, 5086-5091.	3.2	27
21	Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma. Cancer Immunology Research, 2020, 8, 990-1003.	1.6	10
22	Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma. Science Advances, 2020, 6, eaax3223.	4.7	97
23	Melanoma Vaccines. , 2020, , 1243-1265.		0
24	A pilot study of intrahepatic yttriumâ€90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liverâ€only metastases. Cancer Reports, 2019, 2, e1183.	0.6	7
25	Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. , 2019, 7, 241.		19
26	BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death and Disease, 2019, 10, 342.	2.7	125
27	Genomic Analysis of Circulating Tumor DNAÂUsing a Melanoma-Specific UltraSEEK Oncogene Panel. Journal of Molecular Diagnostics, 2019, 21, 418-426.	1.2	18
28	Effectiveness of dabrafenib in the treatment of patients with BRAF V600â€“mutated metastatic melanoma in a Named Patient Program. Melanoma Research, 2019, 29, 527-532.	0.6	6
29	Realâ€world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 26-30.	0.7	18
30	Association of good oncological response to therapy with the development of rheumatic immuneâ€related adverse events following PDâ€1 inhibitor therapy. International Journal of Rheumatic Diseases, 2019, 22, 297-302.	0.9	44
31	Melanoma Vaccines. , 2019, , 1-23.		0
32	Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy. Oncologist, 2018, 23, 849-851.	1.9	46
33	Characterising the phenotypic evolution of circulating tumour cells during treatment. Nature Communications, 2018, 9, 1482.	5.8	86
34	Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide. Nature Communications, 2018, 9, 1026.	5.8	61
35	Long-Term Outcomes in Patients With BRAF V600â€“Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. Journal of Clinical Oncology, 2018, 36, 667-673.	0.8	196
36	Rheumatic immune-related adverse events secondary to antiâ€programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European Journal of Cancer, 2018, 105, 88-102.	1.3	53

#	Article	IF	Citations
37	Perspective: cancer vaccines in the era of immune checkpoint blockade. Mammalian Genome, 2018, 29, 703-713.	1.0	20
38	Isolation and characterization of NY-ESO-1â€“specific T cell receptors restricted on various MHC molecules. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10702-E10711.	3.3	50
39	Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma. Journal of Surgical Oncology, 2018, 118, 915-921.	0.8	16
40	Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmetteâ€“GuÃ©rin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. Frontiers in Immunology, 2018, 9, 411.	2.2	49
41	A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIXâ„¢ adjuvant. Immunotherapy, 2017, 9, 249-259.	1.0	13
42	Whole-genome landscapes of major melanoma subtypes. Nature, 2017, 545, 175-180.	13.7	1,068
43	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. British Journal of Cancer, 2017, 116, 1558-1563.	2.9	91
44	Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist, 2017, 22, 780-e65.	1.9	18
45	Reply to â€˜Comment on â€˜Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyâ€™â€™. British Journal of Cancer, 2017, 116, e15-e15.	2.9	1
46	Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicleâ€“Associated PDGFRÎ². Neoplasia, 2017, 19, 932-940.	2.3	50
47	Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. European Journal of Cancer, 2017, 86, 115-124.	1.3	76
48	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2017, 377, 1345-1356.	13.9	3,589
49	Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell, 2017, 170, 1109-1119.e10.	13.5	1,124
50	CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature, 2017, 549, 101-105.	13.7	624
51	PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation. Molecular Cancer, 2017, 16, 112.	7.9	44
52	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2017, 35, 3815-3822.	0.8	244
53	Optimizing combination dabrafenib and trametinib therapy in BRAF mutationâ€positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 5-12.	0.7	22
54	Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations. BMC Cancer, 2016, 16, 726.	1.1	15

#	Article	IF	Citations
55	Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells. BMC Cancer, 2016, 16, 134.	1.1	27
56	Systems analysis identifies miR-29b regulation of invasiveness in melanoma. Molecular Cancer, 2016, 15, 72.	7.9	21
57	Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces. Scientific Reports, 2016, 6, 19709.	1.6	8
58	Mismatch in epitope specificities between IFNÎ³ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma. , 2016, 4, 10.		35
59	Overall Survival and Durable Responses in Patients With BRAF V600â€“Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. Journal of Clinical Oncology, 2016, 34, 871-878.	0.8	266
60	Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro. Stem Cell Reviews and Reports, 2016, 12, 156-161.	5.6	13
61	First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. Targeted Oncology, 2016, 11, 149-156.	1.7	1
62	Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 2015, 47, 683-693.	0.3	9
63	The role of circulating microRNA in hepatocellular carcinoma. Frontiers in Bioscience - Landmark, 2015, 20, 78-104.	3.0	15
64	Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma. Frontiers in Oncology, 2015, 5, 95.	1.3	26
65	Embryonic Chicken Transplantation is a Promising Model for Studying the Invasive Behavior of Melanoma Cells. Frontiers in Oncology, 2015, 5, 36.	1.3	8
66	Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Scientific Reports, 2015, 5, 11198.	1.6	150
67	Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. Clinical Cancer Research, 2015, 21, 5222-5234.	3.2	4
68	Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIXâ„¢ vaccine in patients with advanced melanoma. Cancer Immunology, Immunotherapy, 2015, 64, 507-518.	2.0	31
69	Whole exome sequencing identifies a recurrentRQCD1P131L mutation in cutaneous melanoma. Oncotarget, 2015, 6, 1115-1127.	0.8	40
70	Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion. Oncotarget, 2015, 6, 15953-15965.	0.8	34
71	Optimal Effector Functions in Human Natural Killer Cells Rely upon Autocrine Bone Morphogenetic Protein Signaling. Cancer Research, 2014, 74, 5019-5031.	0.4	22
72	Effects of Epithelial to Mesenchymal Transition on T Cell Targeting of Melanoma Cells. Frontiers in Oncology, 2014, 4, 367.	1.3	29

#	Article	IF	Citations
73	Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment. Expert Review of Clinical Immunology, 2014, 10, 1107-1123.	1.3	2
74	Sphingosineâ€1â€phosphate lyase is expressed by CD68⁺ cells on the parenchymal side of marginal reticular cells in human lymph nodes. European Journal of Immunology, 2014, 44, 2425-2436.	1.6	17
75	Evolving role of tumor antigens for future melanoma therapies. Future Oncology, 2014, 10, 1457-1468.	1.1	15
76	Clinical and pathological associations of the activating <scp>RAC</scp>1 P29S mutation in primary cutaneous melanoma. Pigment Cell and Melanoma Research, 2014, 27, 1117-1125.	1.5	51
77	Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens. International Journal of Cancer, 2014, 135, 1842-1851.	2.3	20
78	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF^{V600}-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. Journal of Clinical Oncology, 2014, 32, 3697-3704.	0.8	173
79	FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.. Oncotarget, 2014, 5, 264-276.	0.8	38
80	Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma. Oncotarget, 2014, 5, 5782-5797.	0.8	109
81	Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy. Cancer Immunology, Immunotherapy, 2013, 62, 321-335.	2.0	31
82	BRAF Inhibitorâ€"Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition. Journal of Clinical Oncology, 2013, 31, e448-e451.	0.8	51
83	Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. BMC Medical Genomics, 2013, 6, 40.	0.7	28
84	The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel. Pigment Cell and Melanoma Research, 2013, 26, 597-600.	1.5	49
85	Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patientsâ€™ sera using short overlapping peptides and full-length recombinant protein. Molecular Immunology, 2013, 54, 465-471.	1.0	9
86	<scp>F</scp>lt3 ligand expands <scp>CD</scp>4⁺<scp>F</scp>ox<scp>P</scp>3⁺ regulatory <scp>T</scp> cells in human subjects. European Journal of Immunology, 2013, 43, 533-539.	1.6	47
87	Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP. Cancer Cell, 2013, 23, 618-633.	7.7	136
88	Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma. Clinical Cancer Research, 2013, 19, 4021-4023.	3.2	13
89	A comprehensive promoter landscape identifies a novel promoter for CD133 in restricted tissues, cancers, and stem cells. Frontiers in Genetics, 2013, 4, 209.	1.1	10
90	Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. New England Journal of Medicine, 2012, 367, 1694-1703.	13.9	2,445

#	Article	IF	Citations
91	FOXP3 is not mutated in human melanoma. Pigment Cell and Melanoma Research, 2012, 25, 398-400.	1.5	5
92	A Novel HLA-B18 Restricted CD8+ T Cell Epitope Is Efficiently Cross-Presented by Dendritic Cells from Soluble Tumor Antigen. PLoS ONE, 2012, 7, e44707.	1.1	7
93	Stem Cell Media Culture of Melanoma Results in the Induction of a Nonrepresentative Neural Expression Profile. Stem Cells, 2012, 30, 336-343.	1.4	14
94	A novel method for detecting antigen-specific human regulatory T cells. Journal of Immunological Methods, 2012, 377, 56-61.	0.6	5
95	A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma. PLoS ONE, 2012, 7, e48424.	1.1	52
96	Melanoma vaccines: developments over the past 10 years. Expert Review of Vaccines, 2011, 10, 853-873.	2.0	27
97	Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIXâ„¢. Cancer Immunology, Immunotherapy, 2011, 60, 1625-1637.	2.0	41
98	The Ets Transcription Factor ELF5 Functions as a Tumor Suppressor in the Kidney. Twin Research and Human Genetics, 2011, 14, 316-322.	0.3	16
99	Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery. Blood, 2010, 116, 218-225.	0.6	31
100	Cancer vaccines: Where are we going?. Asia-Pacific Journal of Clinical Oncology, 2010, 6, S9-15.	0.7	7
101	Frequent MAGE Mutations in Human Melanoma. PLoS ONE, 2010, 5, e12773.	1.1	22
102	Influenza A Infection Enhances Cross-Priming of CD8+T Cells to Cell-Associated Antigens in a TLR7- and Type I IFN-Dependent Fashion. Journal of Immunology, 2010, 185, 6013-6022.	0.4	34
103	Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1. Expert Review of Vaccines, 2010, 9, 617-629.	2.0	20
104	Cancer stem cells in urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 585-590.	0.8	7
105	ISCOMATRIX Adjuvant Induces Efficient Cross-Presentation of Tumor Antigen by Dendritic Cells via Rapid Cytosolic Antigen Delivery and Processing via Tripeptidyl Peptidase II. Journal of Immunology, 2009, 182, 1253-1259.	0.4	91
106	Melan-Aâ€“specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4. Clinical Cancer Research, 2009, 15, 2507-2513.	3.2	96
107	CT-X antigen expression in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13493-13498.	3.3	92
108	Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial. Clinical Cancer Research, 2009, 15, 2123-2129.	3.2	127

#	Article	IF	Citations
109	Regulatory T-Cellâ€“Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma. Clinical Cancer Research, 2009, 15, 2166-2173.	3.2	119
110	A Long, Naturally Presented Immunodominant Epitope from NY-ESO-1 Tumor Antigen: Implications for Cancer Vaccine Design. Cancer Research, 2009, 69, 1046-1054.	0.4	48
111	Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunology, Immunotherapy, 2009, 58, 1635-1646.	2.0	63
112	Targeted agents for the systemic treatment of advanced hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 76-86.	0.7	2
113	Distinctive localization of antigen-presenting cells in human lymph nodes. Blood, 2009, 113, 1257-1267.	0.6	76
114	Activin-A attenuates several human natural killer cell functions. Blood, 2009, 113, 3218-3225.	0.6	61
115	Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2008, 4, 55-67.	0.7	3
116	Cancer exploiting complement: a clue or an exception?. Nature Immunology, 2008, 9, 1205-1206.	7.0	22
117	The Regulatory T Cellâ€“Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells. Cancer Research, 2008, 68, 3001-3009.	0.4	161
118	P2Y receptor signaling regulates phenotype and IFN-Î± secretion of human plasmacytoid dendritic cells. Blood, 2008, 111, 3062-3069.	0.6	48
119	Activin-A: a novel dendritic cellâ€“derived cytokine that potently attenuates CD40 ligandâ€“specific cytokine and chemokine production. Blood, 2008, 111, 2733-2743.	0.6	98
120	An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma. Clinical Cancer Research, 2007, 13, 3630-3636.	3.2	149
121	Immunotherapy of advanced or metastatic melanoma. Clinical Advances in Hematology and Oncology, 2007, 5, 994-1006.	0.3	11
122	Directed evolution for improved secretion of cancerâ€“testis antigen NY-ESO-1 from yeast. Protein Expression and Purification, 2006, 48, 232-242.	0.6	33
123	Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients. Journal of Immunotherapy, 2006, 29, 499-511.	1.2	62
124	Directions in the immune targeting of cancer: Lessons learned from the cancerâ€testis Ag NYâ€ESOâ€1. Immunology and Cell Biology, 2006, 84, 303-317.	1.0	96
125	A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2006, 58, 157-164.	1.1	7
126	Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage. Clinical Cancer Research, 2006, 12, 764-771.	3.2	212

#	Article	IF	Citations
127	Striking Immunodominance Hierarchy of Naturally Occurring CD8+ and CD4+ T Cell Responses to Tumor Antigen NY-ESO-1. Journal of Immunology, 2006, 176, 5908-5917.	0.4	37
128	Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. Blood, 2005, 105, 1582-1589.	0.6	198
129	Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood, 2005, 105, 2465-2472.	0.6	175
130	Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immunity, 2005, 5, 3.	3.2	10
131	Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. Cancer Immunity, 2005, 5, 5.	3.2	22
132	Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1. Clinical Cancer Research, 2004, 10, 8396-8404.	3.2	55
133	Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9363-9368.	3.3	82
134	NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors. Clinical Cancer Research, 2004, 10, 2879-2890.	3.2	84
135	A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. Journal of Immunological Methods, 2004, 291, 51-62.	0.6	29
136	Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood, 2004, 103, 1391-1397.	0.6	164
137	Dendritic cell development. , 2004, , 103-112.		0
138	The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immunity, 2004, 4, 9.	3.2	58
139	Rational approaches to human cancer immunotherapy. Journal of Leukocyte Biology, 2003, 73, 3-29.	1.5	109
140	ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood, 2003, 102, 613-620.	0.6	118
141	Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood, 2003, 102, 1753-1763.	0.6	103
142	Large Scale Identification of Human Hepatocellular Carcinoma-Associated Antigens by Autoantibodies. Journal of Immunology, 2002, 169, 1102-1109.	0.4	176
143	IFNâ€Î± enhances CD40 ligandâ€mediated activation of immature monocyteâ€derived dendritic cells. International Immunology, 2002, 14, 367-380.	1.8	117
144	CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11813-11818.	3.3	83

#	Article	IF	Citations
145	Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood, 2002, 100, 1362-1372.	0.6	338
146	IL-1Î² Enhances CD40 Ligand-Mediated Cytokine Secretion by Human Dendritic Cells (DC): A Mechanism for T Cell-Independent DC Activation. Journal of Immunology, 2002, 168, 713-722.	0.4	108
147	Exogenous Peptides Presented by Transporter Associated with Antigen Processing (TAP)-Deficient and TAP-Competent Cells: Intracellular Loading and Kinetics of Presentation. Journal of Immunology, 2001, 167, 2529-2537.	0.4	52
148	Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: Relation to disease severity, multiple organ dysfunction, and mortality. Critical Care Medicine, 2000, 28, 2344-2354.	0.4	44
149	Enhancement of Platelet Recovery After Myelosuppressive Chemotherapy by Recombinant Human Megakaryocyte Growth and Development Factor in Patients With Advanced Cancer. Journal of Clinical Oncology, 2000, 18, 2852-2861.	0.8	59
150	Pharmacokinetic Analysis of Pegylated Megakaryocyte Growth and Development Factor in Humans. Growth Factors, 2000, 18, 215-226.	0.5	8
151	Multicycle High-Dose Chemotherapy and Filgrastim-Mobilized Peripheral-Blood Progenitor Cells in Women With High-Risk Stage II or III Breast Cancer: Five-Year Follow-Up. Journal of Clinical Oncology, 1999, 17, 82-82.	0.8	21
152	Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects. Cancer Immunology, Immunotherapy, 1998, 47, 191-197.	2.0	7
153	Immunotherapy of melanoma: Targeting defined antigens. Australasian Journal of Dermatology, 1997, 38, S66-S72.	0.4	9
154	Clinical promise of tumour immunology. Lancet, The, 1997, 349, S19-S22.	6.3	34
155	Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet, The, 1996, 348, 1279-1281.	6.3	216
156	Endogenous haemopoietic growth factors in neutropenia and infection. British Journal of Haematology, 1994, 86, 265-274.	1.2	164
157	The dissociation of GMâ€CSF efficacy from toxicity according to route of administration: a pharmacodynamic study. British Journal of Haematology, 1992, 80, 144-150.	1.2	27
158	Identifying and targeting determinants of melanoma cellular invasion. Oncotarget, 0, 7, 41186-41202.	0.8	35